A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II
study id #: NCT04573023
condition: Mucopolysaccharidosis II
status: Recruiting
purpose:A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
intervention: JR-141, Idursulfase, JR-141 or Idursulfase
results: https://clinicaltrials.gov/ct2/show/results/NCT04573023
last updated: February 26, 2022
-
Genome Editing in Mucopolysaccharidoses and MucolipidosesMucopolysaccharidoses (MPS) and mucolipi...
-
Awake Airway Endoscopy in Mucopolysaccharidosis: A Case ReportMucopolysaccharidosis (MPS) are a group ...
-
Molecular Basis of Mucopolysaccharidosis IVA (Morquio a Syndrome): A Review and Classification of GALNS Gene Variant...Mucopolysaccharidosis IVA (MPS IVA, Morq...
-
Bob StevensBob Stevens is Group Chief Executive Off...
-
Oxidative Stress in Mucopolysaccharidoses: Pharmacological ImplicationsAlthough mucopolysaccharidoses (MPS) are...
-
Condyle Morphology Among Patients With Mucopolysaccharidosis: An Observational Study of Panoramic RadiographsMucopolysaccharidoses (MPS) are a group ...
-
COVID-19 and MPS Patientshttps://www.youtube.com/watch?v=euwZ_vDW...